Zalicus completes reformulated Z160 Phase 1 clinical trial for pain

Zalicus Inc. (NASDAQ: ZLCS) a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases today announced the successful completion of a Phase 1 clinical trial evaluating the pharmacokinetics and safety of a new formulation of Z160, a novel oral N-type calcium channel blocker. In the study, Z160 demonstrated substantial bioavailability and solubility improvements using a novel, proprietary formulation technology. Based on the data from this study, Zalicus plans to advance Z160 into Phase 2 clinical development for the treatment of neuropathic pain in the second half of 2012. A previous formulation of Z160 was studied in clinical trials of over 200 subjects and was well tolerated.

“We are encouraged by the substantial bioavailability and solubility improvements achieved with the new formulation of Z160 tested in this study”

"We are encouraged by the substantial bioavailability and solubility improvements achieved with the new formulation of Z160 tested in this study," commented Mark H.N. Corrigan, MD, President and CEO of Zalicus. "These data provides us with the confidence that we can achieve appropriate and consistent exposure levels to evaluate Z160's efficacy in pain and we look forward to beginning a Phase 2 clinical study in neuropathic pain in the second half of 2012."

Source Zalicus Inc.